Department of Oncogenetics, A.C. Camargo Cancer Center, Professor Antonio Prudente Street, 211 - Liberdade, São Paulo, SP, 01509-900, Brazil.
Department of Imaging, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Cancer Imaging. 2018 Aug 14;18(1):27. doi: 10.1186/s40644-018-0162-8.
Li-Fraumeni syndrome (LFS) is an autosomal dominant disease that is associated with germline TP53 mutations and it predisposes affected individuals to a high risk of developing multiple tumors. In Brazil, LFS is characterized by a different pattern of TP53 variants, with the founder TP53 p.R337H mutation being predominant. The adoption of screening strategies to diagnose LFS in its early stages is a major challenge due to the diverse spectrum of tumors that LFS patients can develop. The purpose of this study was to evaluate two rounds of whole-body magnetic resonance imaging (WB-MRI) which were conducted as a screening strategy for LFS patients.
Over a 4-year period, 59 LFS patients underwent two rounds of WB-MRI. Each MRI was characterized as positive or negative, and positive cases were further investigated to establish a diagnosis. The parameters used to evaluate the WB-MRI results included: positive rate, number of invasive investigations of positive results, and cancer detection rate.
A total of 118 WB-MRI scans were performed. Positive results were associated with 11 patients (9.3%). Seven of these patients (11.8%) were identified in the first round of screening and 4 patients (6.7%) were identified in the second round of screening. Biopsies were performed in three cases (2.5%), two (3.4%) after the first round of screening and one (1.7%) after the second round of screening. The histopathological results confirmed a diagnosis of cancer for all three cases. There was no indication of unnecessary invasive procedures.
WB-MRI screening of LFS carriers diagnosed cancers in their early stages. When needed, positive results were further examined with non-invasive imaging techniques. False positive results were less frequent after the first round of WB-MRI screening.
李-佛美尼综合征(Li-Fraumeni syndrome,LFS)是一种常染色体显性疾病,与种系 TP53 突变相关,使受影响个体易患多种肿瘤。在巴西,LFS 的 TP53 变体模式具有不同特征,以创始人 TP53 p.R337H 突变为主要形式。由于 LFS 患者可能发展出多种肿瘤,因此采用筛查策略早期诊断 LFS 是一项重大挑战。本研究旨在评估两轮全身磁共振成像(Whole-body magnetic resonance imaging,WB-MRI)作为 LFS 患者的筛查策略。
在 4 年期间,59 名 LFS 患者接受了两轮 WB-MRI 检查。每轮 MRI 检查结果均被定义为阳性或阴性,阳性病例进一步进行调查以明确诊断。用于评估 WB-MRI 结果的参数包括:阳性率、阳性结果的侵袭性调查数量和癌症检出率。
共进行了 118 次 WB-MRI 扫描。阳性结果与 11 名患者(9.3%)相关。这 11 名患者中有 7 名(11.8%)在第一轮筛查中发现,4 名(6.7%)在第二轮筛查中发现。对其中 3 例(2.5%)患者进行了活检,2 例(3.4%)在第一轮筛查后进行,1 例(1.7%)在第二轮筛查后进行。所有 3 例的组织病理学结果均证实为癌症。未出现不必要的侵袭性操作。
对 LFS 携带者进行 WB-MRI 筛查可在早期诊断癌症。必要时,采用非侵袭性成像技术进一步检查阳性结果。第一轮 WB-MRI 筛查后,假阳性结果的频率较低。